drugset / Trial / NCT06233877

Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer

NCT06233877

Phase 2 Not yet recruiting 60 enrolled Hirschfeld Oncology
NaSingle-groupOpen-labelTreatment

Summary

The study focuses on advanced metastatic pancreatic cancer, testing a combination of low-dose anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) with the addition of Mitomycin C. The aim is to find a safer and more effective therapy for this devastating disease.

Timeline

Start
2024-03-15
Primary completion
2027-01-31
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule
Subject Irinotecan Small molecule
Subject Leucovorin Small molecule
Subject Mitomycin C Other / unclassified
Subject Oxaliplatin Small molecule
Subject fluorouracil Small molecule